BOSTON, April 10, 2017 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it will host a Key Opinion Leader breakfast meeting focused on rare pediatric liver diseases at the Lotte New York Palace in New York City on Wednesday, April 12, 2017, from 8:00 a.m. to 9:30 a.m. ET.
The meeting will feature a presentation by Philip Rosenthal, MD, an internationally renowned pediatric liver disease specialist. Dr. Rosenthal will discuss the current treatment landscape and unmet medical need in the treatment of children with progressive familial intrahepatic cholestasis (PFIC) and be available to answer questions following the breakfast.
Additionally, Albireo executives will provide an overview of the clinical program for A4250, an ileal bile acid transporter (IBAT) inhibitor in development to treat patients with PFIC and potentially other rare pediatric cholestatic liver diseases.
Dr. Rosenthal is the Director of Pediatric Hepatology, Medical Director of Pediatric Liver Transplant Program and a Professor of Pediatrics and Surgery at the University of California, San Francisco (UCSF). He is board certified in Pediatrics and Pediatric Gastroenterology and has a certificate of added qualification in Transplant Hepatology. Dr. Rosenthal completed his medical training at Downstate Medical Center and the Albert Einstein College of Medicine in New York and a fellowship in pediatric gastroenterology at UCSF. He joined the UCSF faculty in 1995 after serving as Professor of Pediatrics at the University of California, Los Angeles. Dr. Rosenthal’s current research includes several NIH-funded studies (CHiLDReN, NASH CRN, HBV CRN, PALFSG, iWITH) and several industry-sponsored hepatitis B and C research trials.
To confirm your attendance at the KOL breakfast meeting, email or contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. Please RSVP in advance if you plan to attend, as space is limited.
A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170412/reg.jsp and on the Investors section of Albireo’s website at http://ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. The archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit http://www.albireopharma.com.
Source: Albireo Pharma, Inc.
CONTACT: Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 firstname.lastname@example.org